Metabolically Engineered Cell for 3-Fucosyllactose Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing fucosylated compounds, such as 3-fucosyllactose, are inefficient and costly, limiting their availability for applications in promoting digestive health and immune protection.
Innovation Solution
A method involving a fucosyltransferase with alpha-1,3-fucosyltransferase activity is used to catalyze the transfer of a fucose residue from GDP-fucose to a saccharide substrate, producing fucosylated compounds like 3-fucosyllactose, utilizing a metabolically engineered cell to enhance production efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional methods are used for producing fucosylated compounds, then production cost is high and efficiency is low, but availability for biomedical applications is limited
Solution Approach 1:
The patent changes the biochemical parameters of the production system by introducing specific fucosyltransferase enzymes with optimized catalytic activity and selecting metabolically engineered cell lines with enhanced GDP-fucose pools, thereby increasing production efficiency while controlling costs through biological optimization rather than chemical synthesis
Solution Approach 2:
The metabolically engineered cells are designed to self-produce GDP-fucose, the activated sugar donor required for fucosylation, through endogenous fucose metabolism pathways. This eliminates the need for external supplementation of expensive substrates and enables sustained high-yield production of fucosylated compounds
2Productivity
If fucosyltransferase catalyzes the transfer of fucose residue from GDP-fucose to saccharide substrate, then fucosylated compounds are produced, but production efficiency is limited by substrate availability and enzyme activity
Solution Approach 1:
The metabolically engineered cells are pre-configured with enhanced fucose biosynthesis pathways before the fucosylation reaction occurs. This preliminary metabolic preparation ensures that GDP-fucose is continuously available at high concentrations, preventing substrate limitation during compound production
Solution Approach 2:
The engineered cell line performs multiple functions simultaneously: it generates GDP-fucose through endogenous metabolism, provides the saccharide substrate, and supports fucosyltransferase activity. This multi-functionality integrates substrate production and compound synthesis into a single efficient system
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the efficient and cost-effective production of fucosylated compounds, addressing the limitations of existing methods and increasing their availability for biomedical applications.
Implementation Method 1
a fucosyltransferase that has alpha-1,3-fucosyltransferase activity on the N-acetylglucosamine (GlcNAc) and/or the glucose (Glc) residue of Gal-β1,m-GlcNAc-β1,n-Gal-β1,4-Glc of a saccharide substrate
Implementation Method 2
the fucosyltransferase catalyses the transfer of a fucose residue from said GDP-fucose to the GlcNAc and/or Glc residue of said Gal-β1,m-GlcNAc-β1,n-Gal-β1,4-Glc of said saccharide substrate in an alpha-1,3-glycosidic linkage
Data Source
AI summary
This disclosure is in the technical field of synthetic biology, metabolic engineering and cell cultivation. The disclosure describes methods for the production of a fucosylated compound using a fucosyltransferase as well as the purification of the fucosylated compound, the fucosyltransferase having alpha-1,3-fucosyltransferase activity on the N-acetylglucosamine (GlcNAc) and/or the glucose (Glc) residue of Gal-β1,m-GlcNAc-β1,n-Gal-β1,4-Glc of a saccharide substrate comprising Gal-β1,m-GlcNAc-β1,n-Gal-β1,4-Glc wherein the m is 3 or 4 and the n is 3 or 6. The disclosure also provides a cell for production of a fucosylated compound. Next, the disclosure describes methods for the production of 3-fucosyllactose (3-FL) using a fucosyltransferase having alpha-1,3-fucosyltransferase activity on the Glc residue of lactose, as well as the purification of the 3-FL. The disclosure also provides a cell for production of 3-FL.